The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Early look at data for CAR-T bb21217 in R/R MM
Noopur Raje
• 4 Dec 2018
bb21217 is a next-generation anti-BCMA CAR T-cell therapy, which has shown promising results for the treatment of relapsed/refractory multiple myeloma (MM). Here, Noopur Raje, MD, of Massachusetts General Hospital, Boston, MA, discusses the safety and efficacy of bb21217 from the Phase I dose escalation CRB-402 trial (NCT03274219) that was presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
